Translational Relevance
Side effects of doxorubicin limit its clinical application. A delivery system which exploits albumin as a drug carrier was created to increase the therapeutic potential of anthracyclines. INNO-206 is an albumin-binding prodrug of doxorubicin that is released from albumin under acidic conditions, which occurs in the extracellular tissue of tumors.
In vitro, we demonstrate the acid-dependent anti-MM activity of INNO-206 and its superior cytotoxic effects when compared to doxorubicin. Using clinically achievable doses, INNO-206 produced significant anti-MM effects in vivo whereas free doxorubicin at the same or lower doses was toxic. Similar anti-MM effects were obtained in a different model and enhanced anti-MM effects were observed when INNO-206 was combined with bortezomib compared to either agent alone. should provide MM patients with a new anthracycline that may be able to be administered at higher doses compared to free doxorubicin, resulting in superior anti-MM efficacy and improved tolerability.
Introduction
Multiple myeloma (MM) is a malignancy of bone marrow (BM)-based plasma cells that comprises 1% of all malignancies in the United States (1) and is the second most common hematological cancer (2) . Doxorubicin is an active anti-neoplastic drug (3-4) but its clinical application is limited by its side effects (5) (6) (7) . In order to increase the therapeutic potential of this agent while reducing its side effects, several delivery systems have been created, including the development of its pegylated liposomal formulation (PLD) (8) (9) (10) . PLD has shown improved efficacy when combined with bortezomib compared to bortezomib alone for previously treated MM patients (11) . This combination with oral dexamethasone has also been evaluated in untreated patients (12) . This led to a high response rate but was associated with significant toxicity. We have demonstrated using our MM xenograft models that more frequent dosing of PLD at lower doses is more effective and better tolerated than higher doses administered less often (13) . We have used this approach for treating MM patients (14, 15) by combining PLD with bortezomib and intravenous (i.v.) dexamethasone using a longer cycle with high response rates with improved tolerability. Doxorubicin has also been combined with bortezomib and dexamethasone with high response rates but was poorly tolerated (16) .
Hypoxia in tumors has been shown to promote a lethal cancer phenotype through, in part, the induction of hypoxia-inducible factor (HIF)-1, which controls the expression of angiogenesis-related genes that contribute to tumor progression (17) . Anti-angiogenic therapy represents a promising approach for cancer treatment (18) . Anthracyclines, including doxorubicin, reduce HIF-1 levels within tumor cells and inhibit tumor blood vessel development as we and others have shown (19, 20) . INNO-206 (CytRx Corporation, Los Angeles, CA) is an albumin-binding prodrug of doxorubicin that binds rapidly and selectively to the cysteine-34 position of serum albumin after i.v administration and is released under acidic conditions (21) . The BM of MM patients has a strong osteolytic component (22) (23) (24) and osteoclasts accumulate around bone that is adjacent to myeloma cells (25) . Osteoclasts dissolve bone mineral through secretion of hydrochloric acid (26) (27) (28) , and pH measurements at the active osteoclast's ruffled border have shown pH levels of 3 to 4 (29) . Osteoclasts remove the acidified products and liberate them into the extracellular space (30, 31) adjacent to MM cells. These studies suggest that the pH in MM BM is acidic. The extracellular component of tumor tissues is also acidic (32) (33) (34) . Importantly, the majority of chemotherapeutic drugs being weak bases are protonated extracellularly by tumor tissues which reduces their cytotoxicity (33, 35) . Compared to doxorubicin, the acid-dependent release of INNO-206 offers the opportunity to achieve higher levels of active doxorubicin near and within tumor cells.
Evaluation of INNO-206 in solid tumor xenograft models and murine renal cell carcinoma and orthotopic pancreatic carcinoma models, has demonstrated superior efficacy compared to free doxorubicin (21, 36) . Additionally, it exhibits a substantial increase in the maximum tolerated dose (MTD) in animals when compared to conventional doxorubicin (37) . Clinically, INNO-206 showed a good safety profile in a phase 1 clinical trial and induced regressions of solid tumors known to be anthracycline-sensitive (38) . However, INNO-206 has not been previously evaluated in any hematological malignancy. Thus, we conducted our study to ascertain its anti-angiogenic and anti-MM effects in vitro and determine the tolerability and anti-MM 
Preparation of the feather buds
The FBs were prepared as previously described (20) . Briefly, fertilized chick eggs (Charles River, Wilmington, MA, USA) were incubated horizontally for 8 days. Stage 33 chick embryonic dorsal skin with FBs was collected, cut into 2x2 mm sections, and placed on culture inserts in 6-well culture dishes (Falcon). The FBs were cultured with or without drugs for 48 h. Images were analyzed using dissection microscopy to determine size, area, shape factor, and orientation of FBs.
CAM/FB co-culture
For the CAM/FB co-culture, fertilized chick eggs were incubated and windowed by day 8 (20) . The FBs were transferred onto the CAM of an 8-day-old chick embryo. The eggs were sealed and incubated for an additional 4 days. Following this, FB development was determined using microscopy and photographs were taken. Expression of the endothelial gene Flk-1 was determined in the FB using RT-PCR. At least three independent experiments were carried out and each showed similar results.
RT-PCR and densitometry
Total RNA was isolated from each FB. RNA was re-suspended in 0.1% diethyl pyrocarbonate-treated water, digested with DNase I (Sigma-Aldrich, St. Louis, MO, USA) to remove contaminating DNA and extracted with phenol/chloroform followed by ethanol precipitation. Total RNA (1 µg) was reversed-transcribed to cDNA and amplified using the ThermoScript System (Invitrogen, Carlsbad, CA, USA). PCR was performed using the ThermoScript System and a GeneAmp PCR System 9700 (Applied Biosystems. Statistical significance of differences observed in drug-treated mice versus control mice was determined using a Student's t test. The minimal level of significance was P < 0.05. the lower pH. Because the data above was generated from drugs incubated at physiologic pH and at pH 5, the effect of an acidic pH alone on MM cell lines was also tested.
Exposure of MM cells to pH 5 only resulted in a minimal reduction in viable cells compared to those cultured at pH 7. A representative example from all three cell lines tested is shown in Figure 1D .
Anti-angiogenic effect of INNO-206
We assessed the anti-angiogenic effects of INNO-206 at decreasing pH levels using our CAM/FB model (20) . The FB was exposed to INNO-206 or doxorubicin for 2 days followed by attachment to the CAM for an additional 4 days. As controls, FBs that were not previously exposed to INNO-206 were attached to the CAM. Placode and dermal condensation of the FB occurred and the weight of the FB increased and feathers formed.
In the presence of INNO-206, inhibition of FB development occurred in a concentrationand pH-dependent manner after 4 days of culture (Figure 2A ). Similar to our previous published results (20) , doxorubicin inhibited feather development ( Figure 2B ). Next, we assessed endothelial gene expression in the FB tissue following attachment to the CAM.
Specifically, Flk-1 transcript levels were assessed using RT-PCR, and RNA levels were post-tumor implantation. By day 28, the remaining two mice from each of these three groups died ( Figure 5D ). Furthermore, by day 35, all mice receiving PLD died and all mice receiving vehicle control and single-agent bortezomib were alive (data not shown).
Visualization of Evans blue dye-albumin complexes within three different MM xenografts
To demonstrate albumin uptake within the MM xenograft tumors, and because INNO-206 is doxorubicin bound to albumin, the Evans blue dye, a compound which irreversibly and rapidly binds to plasma albumin, was injected i. 
doses in a rat model (43) , and significantly lower levels of INNO-206 were observed in the heart, liver and kidneys of mice when compared to similar studies assessing doxorubicin (21) . The lack of deaths observed in our in vivo study with INNO-206 is consistent with a favorable shift in the lethal dose, which is 2-to 5-fold higher for INNO-206 compared to free doxorubicin (37, 44) . compared to the highest dose of doxorubicin that can be safely administered (38) . Results from our LAGκ-1A xenograft study provide further evidence that INNO-206 is able to be given safely at much higher doses than conventional doxorubicin. Preclinical xenograft studies performed in other laboratories in solid cancers have similarly shown to be more efficacious than free doxorubicin and that more of this novel anthracycline can be administered than doxorubicin (36).
We and others have shown that the anti-MM activity of doxorubicin is enhanced in the presence of bortezomib in vitro and in vivo (45) . Clinically, one of the first effective combination chemotherapy treatments for relapsed/refractory MM included doxorubicin with vincristine and oral dexamethasone which rapidly gained widespread use in the frontline setting (3). Doxorubicin has also been combined with bortezomib and dexamethasone in the first line setting in MM patients with high response rates (16 
and reduced toxicity compared to doxorubicin (8) but it cannot be administered at higher doses than doxorubicin. Like doxorubicin, PLD has also been combined with bortezomib for previously treated MM patients (11) and both drugs with dexamethasone for previously untreated and relapsed or refractory MM patients (12, 14, 15) . However, patients continue to show resistant disease and significant side effects with PLD-based therapies. Thus, we examined the effect of the combination of INNO-206 and bortezomib in another human MM xenograft model. Although initially single agent and combination therapies showed similar anti-MM effects, the combination of both agents proved superior with longer follow up. The toxicity profile, as judged by body weight loss and mortality, was similar between mice treated with single-agent and combination treatment.
Additionally, once weekly injection at a higher dose was superior in its anti-MM effects compared to thrice weekly (on consecutive days) at lower doses. In contrast, the toxicity of single agent doxorubicin at 2 mg/kg, when administered once weekly, resulted in the deaths of all mice after only 3 injections, which is consistent with prior studies (46, 47) .
As expected, the addition of bortezomib to doxorubicin or PLD at the MTD dose (2 mg/kg), which is the equivalent of the doxorubicin dose used in the INNO-206 (2.7 mg/kg) plus bortezomib studies, was also not tolerated in these mice and all animals were dead by day 28.
Optimal scheduling of INNO-206 was also evaluated. Our previous results evaluating PLD showed more frequent daily administration at lower doses was more effective than higher doses given on a weekly schedule (13) . Our clinical results with more frequent administration of lower doses of PLD when used in combination with bortezomib and dexamethasone have shown high response rates with reduced toxicity (14, 15) . In Figure 5 . Anti-MM effects of INNO-206 alone at 0.9 mg/kg thrice weekly or 2.7 mg/kg once weekly, bortezomib (Bort) alone or the drugs together in vivo using the LAGκ-2 xenograft model. A, a significant reduction in tumor growth was observed in mice bearing human LAGκ-2 tumors receiving INNO-206 (i.v.) at 2.7 mg/kg once weekly or thrice weekly at 0.9 mg/kg when compared to vehicle control. B, INNO-206 dosed once weekly at 2.7 mg/kg plus bortezomib combination therapy significantly inhibited tumor growth more than either agent alone. C, body weight was used to assess toxicity of treatment and minimal loss was observed in mice dosed with single agents or combination therapy (P = prior to initiation of treatment, E = end of study weight). D, mice did not tolerate doxorubicin or PLD (once weekly at 2 mg/kg, i.v. injection) in combination with bortezomib (twice weekly at 0.5 mg/kg via i.v. injection) and died due to toxicity. Data are presented as means ± standard error of the mean. 
